Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.

Following EMS mutagenesis, three estramustine (EM) resistant DU 145 human prostatic carcinoma cell lines were clonally selected by exposure to incrementally increasing concentrations of the drug. Although only low levels of resistance (approximately 3-fold) were attainable, this resistance was stabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Speicher, L. A., Sheridan, V. R., Godwin, A. K., Tew, K. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977526/
https://www.ncbi.nlm.nih.gov/pubmed/1892755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977526/
https://www.ncbi.nlm.nih.gov/pubmed/1892755

Ejemplares similares